1. In Vivo

Will AI Obviate The Need For Animal Trials?

 
• By David Wild

Quris-AI has built a platform that can simulate genetically diverse clinical trials on a chip. The technology may reduce biopharma’s need for animal testing and de-risk human testing. 

Bio Bytes
• Source: Shutterstock

Israeli-American biotech Quris-AI’s platform can test thousands of drug candidates on hundreds of miniaturized and genetically diverse collections of organs-on-a-chip, effectively creating a “clinical-trial-on-a-chip.” The robust AI-based approach predicts drug toxicity with a level of accuracy that won it a partnership with Merck KGaA.

“This method surpasses the limitations of traditional animal testing by leveraging vast amounts of unique, real-time data to refine machine learning

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.